Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)

Juan C. Ramos, Joseph A. Sparano, Michelle A. Rudek, Page C. Moore, Ethel Cesarman, Erin G. Reid, David Henry, Lee Ratner, David Aboulafia, Jeanette Y. Lee, Richard F. Ambinder, Ronald Mitsuyasu, Ariela Noy

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads. Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+) or human herpesvirus-8-positive (HHV-8+) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). Patients and Methods: We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10 high-risk patients with diffuse large B-cell lymphoma (1 EBV+), 1 EBV+/HHV-8+ primary effusion lymphoma, and 1 unclassifiable NHL. VOR was escalated from 300 to 400 mg using a standard 3 + 3 design based on dose-limiting toxicity observed in cycle 1 of R-EPOCH. Results: The recommended phase II dose of VOR was 300 mg, with dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, significantly altered chemotherapy steady-state concentrations. VOR chemotherapy did not negatively impact CD4+ cell counts or HIV viral loads, which decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with NHL treated with VOR(R)-EPOCH was 100% (complete 83% and partial 17%) with a 1-year event-free survival of 83% (95% confidence interval, 51.6%-97.9%). Conclusion: VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.

Original languageEnglish (US)
Pages (from-to)180-190.e2
JournalClinical Lymphoma, Myeloma and Leukemia
Volume18
Issue number3
DOIs
StatePublished - Mar 1 2018

Fingerprint

Non-Hodgkin's Lymphoma
HIV
Safety
Human Herpesvirus 4
Human Herpesvirus 8
Drug Therapy
Vincristine
Etoposide
CD4 Lymphocyte Count
Prednisone
Viral Load
Doxorubicin
Cyclophosphamide
Disease-Free Survival
vorinostat
Primary Effusion Lymphoma
Histone Deacetylase Inhibitors
Lymphoma, Large B-Cell, Diffuse
B-Cell Lymphoma
Therapeutics

Keywords

  • AIDS-related malignancies
  • Chemotherapy
  • Epstein-Barr virus
  • Histone deacetylase inhibitors
  • Lytic-inducing therapies

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). / Ramos, Juan C.; Sparano, Joseph A.; Rudek, Michelle A.; Moore, Page C.; Cesarman, Ethel; Reid, Erin G.; Henry, David; Ratner, Lee; Aboulafia, David; Lee, Jeanette Y.; Ambinder, Richard F.; Mitsuyasu, Ronald; Noy, Ariela.

In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 18, No. 3, 01.03.2018, p. 180-190.e2.

Research output: Contribution to journalArticle

Ramos, JC, Sparano, JA, Rudek, MA, Moore, PC, Cesarman, E, Reid, EG, Henry, D, Ratner, L, Aboulafia, D, Lee, JY, Ambinder, RF, Mitsuyasu, R & Noy, A 2018, 'Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)', Clinical Lymphoma, Myeloma and Leukemia, vol. 18, no. 3, pp. 180-190.e2. https://doi.org/10.1016/j.clml.2018.01.004
Ramos, Juan C. ; Sparano, Joseph A. ; Rudek, Michelle A. ; Moore, Page C. ; Cesarman, Ethel ; Reid, Erin G. ; Henry, David ; Ratner, Lee ; Aboulafia, David ; Lee, Jeanette Y. ; Ambinder, Richard F. ; Mitsuyasu, Ronald ; Noy, Ariela. / Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075). In: Clinical Lymphoma, Myeloma and Leukemia. 2018 ; Vol. 18, No. 3. pp. 180-190.e2.
@article{87994c2629cb44cd92a0bea52add8eb6,
title = "Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)",
abstract = "We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83{\%} and 1-year event-free survival of 83{\%}. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads. Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+) or human herpesvirus-8-positive (HHV-8+) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). Patients and Methods: We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10 high-risk patients with diffuse large B-cell lymphoma (1 EBV+), 1 EBV+/HHV-8+ primary effusion lymphoma, and 1 unclassifiable NHL. VOR was escalated from 300 to 400 mg using a standard 3 + 3 design based on dose-limiting toxicity observed in cycle 1 of R-EPOCH. Results: The recommended phase II dose of VOR was 300 mg, with dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, significantly altered chemotherapy steady-state concentrations. VOR chemotherapy did not negatively impact CD4+ cell counts or HIV viral loads, which decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with NHL treated with VOR(R)-EPOCH was 100{\%} (complete 83{\%} and partial 17{\%}) with a 1-year event-free survival of 83{\%} (95{\%} confidence interval, 51.6{\%}-97.9{\%}). Conclusion: VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.",
keywords = "AIDS-related malignancies, Chemotherapy, Epstein-Barr virus, Histone deacetylase inhibitors, Lytic-inducing therapies",
author = "Ramos, {Juan C.} and Sparano, {Joseph A.} and Rudek, {Michelle A.} and Moore, {Page C.} and Ethel Cesarman and Reid, {Erin G.} and David Henry and Lee Ratner and David Aboulafia and Lee, {Jeanette Y.} and Ambinder, {Richard F.} and Ronald Mitsuyasu and Ariela Noy",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.clml.2018.01.004",
language = "English (US)",
volume = "18",
pages = "180--190.e2",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
number = "3",

}

TY - JOUR

T1 - Safety and Preliminary Efficacy of Vorinostat With R-EPOCH in High-risk HIV-associated Non-Hodgkin's Lymphoma (AMC-075)

AU - Ramos, Juan C.

AU - Sparano, Joseph A.

AU - Rudek, Michelle A.

AU - Moore, Page C.

AU - Cesarman, Ethel

AU - Reid, Erin G.

AU - Henry, David

AU - Ratner, Lee

AU - Aboulafia, David

AU - Lee, Jeanette Y.

AU - Ambinder, Richard F.

AU - Mitsuyasu, Ronald

AU - Noy, Ariela

PY - 2018/3/1

Y1 - 2018/3/1

N2 - We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads. Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+) or human herpesvirus-8-positive (HHV-8+) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). Patients and Methods: We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10 high-risk patients with diffuse large B-cell lymphoma (1 EBV+), 1 EBV+/HHV-8+ primary effusion lymphoma, and 1 unclassifiable NHL. VOR was escalated from 300 to 400 mg using a standard 3 + 3 design based on dose-limiting toxicity observed in cycle 1 of R-EPOCH. Results: The recommended phase II dose of VOR was 300 mg, with dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, significantly altered chemotherapy steady-state concentrations. VOR chemotherapy did not negatively impact CD4+ cell counts or HIV viral loads, which decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with NHL treated with VOR(R)-EPOCH was 100% (complete 83% and partial 17%) with a 1-year event-free survival of 83% (95% confidence interval, 51.6%-97.9%). Conclusion: VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.

AB - We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma. VOR was tolerable at 300 mg and seemingly efficacious with chemotherapy with complete response rate of 83% and 1-year event-free survival of 83%. VOR did not significantly alter chemotherapy steady-state concentrations, CD4+ cell counts, or HIV viral loads. Introduction: Vorinostat (VOR), a histone deacetylase inhibitor, enhances the anti-tumor effects of rituximab (R) and cytotoxic chemotherapy, induces viral lytic expression and cell killing in Epstein-Barr virus-positive (EBV+) or human herpesvirus-8-positive (HHV-8+) tumors, and reactivates latent human immunodeficiency virus (HIV) for possible eradication by combination antiretroviral therapy (cART). Patients and Methods: We performed a phase I trial of VOR given with R-based infusional EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) (n = 12) and cART in aggressive HIV-associated B-cell non-Hodgkin lymphoma (NHL) in order to identify safe dosing and schedule. VOR (300 or 400 mg) was given orally on days 1 to 5 with each cycle of R-EPOCH for 10 high-risk patients with diffuse large B-cell lymphoma (1 EBV+), 1 EBV+/HHV-8+ primary effusion lymphoma, and 1 unclassifiable NHL. VOR was escalated from 300 to 400 mg using a standard 3 + 3 design based on dose-limiting toxicity observed in cycle 1 of R-EPOCH. Results: The recommended phase II dose of VOR was 300 mg, with dose-limiting toxicity in 2 of 6 patients at 400 mg (grade 4 thrombocytopenia, grade 4 neutropenia), and 1 of 6 treated at 300 mg (grade 4 sepsis from tooth abscess). Neither VOR, nor cART regimen, significantly altered chemotherapy steady-state concentrations. VOR chemotherapy did not negatively impact CD4+ cell counts or HIV viral loads, which decreased or remained undetectable in most patients during treatment. The response rate in high-risk patients with NHL treated with VOR(R)-EPOCH was 100% (complete 83% and partial 17%) with a 1-year event-free survival of 83% (95% confidence interval, 51.6%-97.9%). Conclusion: VOR combined with R-EPOCH was tolerable and seemingly efficacious in patients with aggressive HIV-NHL.

KW - AIDS-related malignancies

KW - Chemotherapy

KW - Epstein-Barr virus

KW - Histone deacetylase inhibitors

KW - Lytic-inducing therapies

UR - http://www.scopus.com/inward/record.url?scp=85042767813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85042767813&partnerID=8YFLogxK

U2 - 10.1016/j.clml.2018.01.004

DO - 10.1016/j.clml.2018.01.004

M3 - Article

C2 - 29426719

AN - SCOPUS:85042767813

VL - 18

SP - 180-190.e2

JO - Clinical Lymphoma, Myeloma and Leukemia

JF - Clinical Lymphoma, Myeloma and Leukemia

SN - 2152-2669

IS - 3

ER -